The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2025 | Topical BRAF inhibitor for EGFR inhibitor-induced acneiform rash
Anisha Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II trial assessing LUT014 gel, a topical BRAF inhibitor, for managing acneiform rash in patients receiving colorectal cancer receiving cetuximab or panitumumab. The study tested two concentrations of LUT014 against placebo, where significant clinical benefit and favorable tolerability were shown for both active treatment arms, highlighting the potential of targeted topical therapy to manage dermatologic toxicity and support uninterrupted anti-EGFR cancer treatment. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
